Navigation Links
Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
Date:1/7/2008

apan the same innovative therapy that is already available to patients in the U.S. and Europe," said Dr. Yuzuru Kanakura, M.D. Ph.D., Professor and Chairman Department of Hematology and Oncology, Osaka University Graduate School of Medicine. "We are excited to be participating in such an important study and look forward to the Soliris program progressing to registration in Japan."

"After consultation with the leading PNH clinical investigators in Japan and with the PMDA, we are pleased to have commenced dosing with Soliris in the AEGIS study, our single Japanese registration trial," said Leonard Bell, M.D., Chief Executive Officer of Alexion. "After completing enrollment and dosing, and comparing these results in Japanese patients to our earlier PNH studies, we expect to submit a licensing application for Soliris in PNH to the Japanese regulatory authority. Initiating this Japanese registration study is an important component of reaching our global goal that every PNH patient who can benefit from Soliris will have access to it."

About PNH

PNH is a rare blood disease that affects an estimated 8,000 to 10,000 people in North America and Europe and, using similar prevalence estimates, potentially 1,000 - 2,000 patients in Japan. (3) PNH often strikes people in the prime of their lives, with an average age of onset in the early 30's. (4) Approximately ten percent of all patients first develop symptoms at 21 years of age or younger. (5) PNH develops without warning and can occur in men and women of all races, backgrounds and ages. PNH often goes unrecognized, with delays in diagnosis often ranging from one to more than 10 years. (6) The estimated median survival for PNH patients is between 10 and 15 years from the time of diagnosis. (4,6)

PNH has been identified more commonly among patients with disorders of the bone marrow, including aplastic anemia (AA) and myelodysplastic syndrome (MDS). (7,8,9,10) In patients with thrombosis of unknown ori
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
2. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
3. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
4. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
5. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
6. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
10. MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
11. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...Newswire/-- FromNovember16-18,Phonak,theleadingman...secondeditionoftheHearingCareforAdultsConference,f...nferencebroughttogetherleadingexpertsinagingandaud...oworkeverydaywitholderpeoplewithhearinglossforanop...archandtrendsinhearingcareforolderpeople. ,, W...
(Date:11/25/2009)...FirstCall/--FormanyofthemillionsofhearingimpairedA... hearingloss ,theholidaysmaynotbeallthathappy,says...esidentofHearUSA(Amex: EAR ),oneofAmerica,slargest...velinkedhearinglosstostress,frustration,andsociali...eringswithfamiliesandfriends,whenmanyofthosewithhe...
(Date:11/25/2009)...-RegadoBiosciences,aprivatelyheldcompanyleadingthe...olagents,announcedthatDavidMazzo,PhD,CEOandPreside...thCareConferenceattheNewYorkPalaceHotelinNewYorkCi...nTuesday,December1andwillincludeanoverviewoftheCom...ram,theanticoagulantsystem,REG1.Thehealthcareindus...
Breaking Medicine Technology:Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Right to Health Care Debated at New ProCon org Website 58181 1Right to Health Care Debated at New ProCon org Website 58181 2Spherix Incorporated Announces Annual Shareholders Meeting Date 14241 1Spherix Incorporated Announces Annual Shareholders Meeting Date 14241 2Spherix Incorporated Announces Annual Shareholders Meeting Date 14241 3Pre clinical Data Show OrbusNeichs Combo Bio engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies 5039 1Pre clinical Data Show OrbusNeichs Combo Bio engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies 5039 2Pre clinical Data Show OrbusNeichs Combo Bio engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies 5039 3
..., Dec. 1 Roche announced today that a,comparative...ved pain and,discomfort associated with blood gluc...ing systems and lancing devices were deemed least ...the ACCU-CHEK Aviva and ACCU-CHEK Compact,Plus blo...lticlix, ACCU-CHEK,Softclix and ACCU-CHEK Softclix...
...TING, Pa., Dec. 1 Genaera Corporation (Nasdaq: ...s begun in study MSI-1436C-102 (Study 102), the mu...ine (MSI-1436) in overweight and obese type 2 diab...atment of type 2 diabetes and obesity which works ... leptin pathways through the highly selective inhi...
Other Medicine Technology:Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3
(Date:11/25/2009)...re/--TheBartleHallConventionCenterwilltemporarilyb...nKansasCityhoststhelatestinaseriesofmassivefreecli...hasthepotentialtobethebiggestoneyet,becauseitwille...sinsteadofoveraweekend,"SheriWood,executivedirecto...ationalAssociationofFreeClinics(NAFC). ,, Atpre...
(Date:11/25/2009)...wire-USNewswire/--AnarticlebyJanetWoodcock,M.D.,di...,titled"ADifficultBalance-PainManagement,DrugSafet...nglandJournalofMedicine. ,, (Logo: http://www.n...nthearticle,WoodcockdiscussesFDAeffortstostrikeaba...tandmanagingtherisksposedbyvariousanalgesics.Asexa...
(Date:11/25/2009)... statistically significant survival benefit from a...ceptor (ER)-positive tumors had high levels of pho...S118-P), according to a brief communication publis...onal Cancer Institute . , Approximately 50% of b...inical studies have shown that ER-alpha S118-P is ...
(Date:11/25/2009)...nd treatment clinics to resume Monday, Nov. 30 , ... 25, 2009 -- Centegra Health System is continuing ...s at four Centegra Primary Care (CPC) vaccination ...ved. The clinics are at CPC sites in Huntley, Wood...s follows: ,   From 4:30 to 7:30 p.m. ...
(Date:11/25/2009)...e-USNewswire/--TheAmericanAssociationforHomecareen...28,whichisdesignedtosubstantiallyimprovetoolsandre...sintroducedbySen.GeorgeLeMieux(R-Fla.). ,, TheL...ciationforHomecareoutlinedinits13-pointanti-frauda...ebruary.Thoseprovisionsincludecallingforreal-timea...
Breaking Medicine News(10 mins):Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2
...red weeks earlier than a decade ago and is likely ...aid . "Despite uncertainties in the magnit...ry, one consistent feature of extant and projected...ute, University of Aarhus, Denmark in the June 19 ...
...ess Margaret Hospital (PMH) are using a new way to...ive radiation therapy , takes less than an hour an...ents. The PMH team combined the expertise of ...irst time the portable intrabeam radiotherapy mach...
... one parent smoking have five times as much cotini...nts whose parents are non-smokers , according to a...ase in Childhood. The study was led by res...ts) and found that having a mother who smoked quad...
...rt is well known. But what is not is that even dur...nges. While diabetes could lead to blindness, limb...w Australian study says that people displaying mer.... Researchers at the International Diabete...
...view of previous studies indicates that two doses ...rovides substantial benefit to HIV-negative women ...ecessary for HIV-positive women. In malaria-e...alaria during their first and second pregnancies, ...
...endered jobless under the new recruitment process ... hardest hit . The new system will undermi...ce. Non-urgent patient care in England could be hi...idelio Group of senior doctors. The group is tryin...
Other Medicine News:Health News:Interoperative Radiotherapy for Breast Cancer Patients 2Health News:Smokers Blow Their Infants Health into Thin Air 2Health News:Even Pre-diabetes can Kill, Australian Study Says 2Health News:Effective Treatment for Malaria Control 2Health News:Effective Treatment for Malaria Control 3Health News:The New Recruitment Process Leaves Thousands of Doctors Jobless 2
Columbus Total Knee System
Shandon Humidity Chamber
Shandon Mini Hotplate
Shandon Histobath 2
Medicine Products: